Skip to main content

Advertisement

Table 2 Clinical outcomes of trastuzumab beyond disease progression

From: Continuing trastuzumab beyond disease progression: outcomes analysis in patients with metastatic breast cancer

Median follow-up 39.6 months
Median duration of trastuzumab therapy 16.5 months
  First-line trastuzumab (n = 57) Second-line trastuzumab (n = 55) Third-line trastuzumab (n = 26) Fourth-line trastuzuamb (n = 12)
Objective response rate     
   CR + PR, (number) percentage (20)a 35 (9)b 16 (4)c 15 (0) 0
   CR, (number) percentage (6) 10.5 (2) 3.5 (0) 0 (0) 0
   PR, (number) percentage (14) 24.5 (7) 12.5 (4) 15 (0) 0
Clinical benefit, percentage (CR + PR + SD) 74 (6 + 14 + 22) 53 (2 + 7 + 20) 60 (0 + 4 + 11) 17 (0 + 0 + 2)
Time to progression in months, median (range) 7.25 (1.5–46.5) 5.25 (1.25–34.2) 5.25 (1–33.5) 3.75 (1–7)
  1. aTwo patients were not evaluable. bFour patients were not evaluable. cOne patient was not evaluable. CR, complete response; PR, partial response; SD, stable disease.